Cancer Network spoke with Kathryn Cecilia Arbour, MD, of Memorial Sloan-Kettering Cancer Center, about the most recent research on checkpoint inhibitors in oncology.
Kathryn Cecilia Arbour, MD
Advertisement
Articles by Kathryn Cecilia Arbour, MD
Advertisement
Latest Updated Articles
Dr. Arbour on the Latest Data for Checkpoint Inhibitors for Lung Cancer in 2019Published: June 11th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
3
Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma
4
What Do Physicians and Patients Think About ADCs as Cancer Treatment?
5
